Skip to main content
OpenTrials
Completed

NCT Number: NCT06048757

Mobile Application-delivered Resistance Program for Children and Adolescents With Type 1 Diabetes (Diactive-1)

This project involves a two-arm randomized controlled trial (RCT) designed to assess the feasibility, acceptability, and preliminary efficacy of a mobile application aimed at prescribing resistance training for children and adolescents with type 1 diabetes (Diactive-1). The program will span 24 weeks, with a minimum weekly frequency of 3 sessions. The researchers aim to recruit 52 participants but will enroll additional participants to account for potential withdrawals and ensure compliance with the desired sample size. The primary objective of the study is to evaluate the impact of the Diactive-1 mobile application on insulin requirements in children and adolescents with Type 1 Diabetes. Additionally, the researchers will investigate the effects of the Diactive-1 program on secondary parameters such as glycemic control, cardiometabolic indicators, physical fitness, and daily physical activity, among others. The hypothesis posits that personalized training through a mobile application, primarily focusing on muscular strength, will effectively reduce the daily insulin dosage in children and adolescents with type 1 diabetes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type 1 Diabetes Autoimmune Diseases Diabetes Mellitus Diabetes Mellitus, Type 1 Endocrine System Diseases Glucose Metabolism Disorders Hyperinsulinism Immune System Diseases Insulin Resistance Metabolic Diseases Nutritional and Metabolic Diseases

Age range

8 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Fundación Miguel Servet/ Navarrabiomed, Pamplona, Navarre, Spain

Loading trial locations.

About this study

The primary objective of this study is to evaluate the effectiveness of the Diactive-1 mobile application, which offers personalized resistance training, in reducing daily insulin requirements among children and adolescents with type 1 diabetes.

To achieve this objective, researchers will conduct a 24 weeks randomized controlled trial involving at least 52 participants diagnosed with type 1 diabetes. The study will consist of two groups: an experimental group utilizing the Diactive-1 application and a control group receiving standard treatment. Participant allocation to either group will be determined through central randomization.

The Diactive-1 intervention encompasses several key features, including: (i) tailoring exercises based on initial physical fitness levels; (ii) adjusting the previous exercise to the glucose level measured through an interstitial glucose monitor or entered manually before the training session; (iii) monitoring heart rate during exercise; (iv) providing the flexibility to train with or without equipment, individually or with a partner; (v) dispensing diabetes management advice before and after each training session; and (vi) adapting training progressions based on session adherence. A face-to-face session will be conducted before commencing the intervention to ensure that participants are familiar with the fundamental movements, thus reducing the risk of potential muscle injuries.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 8-18 years old
  • At least 6 months post-diagnosis for type 1 diabetes
  • Ability to complete measures and intervention program in Spanish
  • Access to broadband or cellular internet
  • Patients who signed the informed consent form prior to participation; for minors, a legal representative must provide consent and sign the informed consent form.

Exclusion criteria

  • Any comorbidity limiting the capacity to participate in physical activity or inadequate understanding of the Spanish language.
  • Participants will be excluded if they don't have access to the internet, lack a smartphone or tablet, or are unable to use the application.

Treatment and study plan

Diactive-1 application

Device

Participants will engage in 24 weeks resistance exercise program with goal of maintaining at least 3 sessions per week with 4-5 exercises per session (13-33 minutes). The training intervention will comprise 3-4 sets of 6-12 repetitions and will consist of a combination of exercises for the upper and lower body and the core, utilizing the participants' body weight as the primary resistance or auxiliary materials such as elastic bands and a water-fillable kettlebell. The load and intensity of the exercise will be based on the number of repetitions, the resistance of the elastic bands and/or the weight of the aquaball, as well as the difficulty of the exercises. A mobile application known as Diactive-1 will be utilized.

Primary outcomes

  1. Change in daily insulin dose requirement

    Time frame: Baseline, 12 and 24 weeks

    The daily insulin dose requirements will be measured in units per kilogram of body weight. Assessment will rely on participant-reported data from insulin pumps or injection logs, gathered for 9 days prior to the intervention, at 12 weeks, and after the intervention.

Secondary outcomes

  1. Change in glycated hemoglobin

    Time frame: Baseline and 24 weeks

    Glycated hemoglobin (measured in percent)

  2. Number of participants with good glycemic control

    Time frame: Baseline and 24 weeks

    Number of participants with a glycated hemoglobin level lower than 7%

  3. Change in time in range

    Time frame: Baseline and 24 weeks

    The percentage of time a person spends with their blood glucose levels in the target range (70-180 mg/dL or 3.9-10 mmol/L) (measured in percent)

  4. Change in time below range

    Time frame: Baseline and 24 weeks

    The percentage of time a person spends with their blood glucose levels below the target range (<70 mg/dL or <3.9 mmol/L, i.e., hypoglycemia) (measured in percent)

  5. Change in time above range

    Time frame: Baseline and 24 weeks

    The percentage of time a person spends with their blood glucose levels above the target range (>180 mg/dL or 10 mmol/L, i.e., hyperglycemia) (measured in percent).

  6. Change in glycemic variability

    Time frame: Baseline and 24 weeks

    Glycemic variability measures the fluctuation in blood glucose levels over time, expressed as a percentage. Lower glycemic variability indicates more stable levels, while higher glycemic variability suggests greater fluctuations.

  7. Change in compliance with 24-hour movement behaviors

    Time frame: Baseline and 24 weeks

    Physical activity at different intensities (average min/day), sedentary time (average min/day) and sleep (average min/day) will be measured using GENEActive accelerometers and self-reported questionnaires

  8. Change in physical activity

    Time frame: Baseline, 12 and 24 weeks

    Physical activity will be estimated using the GENEActive triaxial accelerometer (ActivInsights) and measured in minutes per day

  9. Change in self-reported physical activity

    Time frame: Baseline and 24 weeks

    Aerobic and muscle-strengthening activities will be assessed using two separate ad hoc questions. Participants will have response options ranging from 0 to 7 days per week, with increments of 1 day

  10. Change in sedentary behaviors

    Time frame: Baseline and 24 weeks

    Sedentary behaviors will be self-reported using the Youth Leisure-Time Sedentary Behavior Questionnaire. Total daily sedentary screen time will be calculated by summing the durations of daily screen time activities. Furthermore, total screen time for both weekdays and weekends will be calculated in minutes per day

  11. Change in sleep duration

    Time frame: Baseline and 24 weeks

    Sleep duration will be determined by recording the number of hours slept each day in a 9-day diary

  12. Change in sleep quality

    Time frame: Baseline and 24 weeks

    Sleep quality will be assessed using the Pittsburgh Sleep Quality Index questionnaire, which evaluates seven established aspects of sleep quality: subjective sleep quality, time taken to fall asleep, duration of sleep, sleep efficiency, sleep disturbances (such as nightmares, pain, or feeling too hot or cold), use of sleep medication, and daytime dysfunction. Each question is scored on a scale from 0 to 3, with higher scores indicating more pronounced sleep disturbances.

  13. Change in blood pressure

    Time frame: Baseline and 24 weeks

    Systolic and diastolic blood pressure will be measured in mmHg using a blood pressure monitor

  14. Change in cardio-ankle vascular index (CAVI)

    Time frame: Baseline and 24 weeks

    Measuring Cardio-Ankle Vascular Index (measured in percent) by VaSera VS 2000 (Fukuda Denshi, Japan)

  15. Change in pulse wave velocity

    Time frame: Baseline and 24 weeks

    Measuring pulse wave velocity (m/seg) by VaSera VS 2000 (Fukuda Denshi, Japan)

  16. Change in heart rate variability

    Time frame: Baseline and 24 weeks

    The heart rate will be recorded by a heart rate monitor in a beat-by-beat basis.

  17. Change in disordered eating

    Time frame: Baseline and 24 weeks

    Disordered eating will be screened using the mSCOFF questionnaire. This questionnaire consists of six straightforward yes/no questions. A positive response to two or more of these questions suggests a potential eating disorder, often requiring further evaluation.

  18. Change in Health-Related Quality of Life in the context of a chronic illness

    Time frame: Baseline and 24 weeks

    Health-Related Quality of Life in the context of a chronic illness will be evaluated using the Spanish version of the 'Questionnaire for Young People with Diabetes' (DISABKIDS). This questionnaire consists of 12 questions about how a patient has felt in the last four weeks, with responses rated on a 5-point Likert scale from 1 (Never) to 5 (Always)

  19. Change in Health-Related Quality of Life

    Time frame: Baseline and 24 weeks

    Health-Related Quality of Life will be evaluated using the Screening for and Promotion of Health-Related Quality of Life in Children and Adolescents (KIDSCREEN-10). This is a generic 10-item unidimensional instrument that assesses the functional, mental, and social aspects of well-being in children and adolescents. Each item will offer five response categories, ranging from 'never' to 'always' or from 'not at all' to 'extremely'

  20. Change in subjective well-being

    Time frame: Baseline and 24 weeks

    Subjective well-being will be assessed using the 'Cuestionario Unico de Bienestar Escolar' (CUBE), which comprises five items evaluating different aspects of life satisfaction. All variables will be measured on a 10-point Likert scale ranging from 0 to 10 (0 = totally disagree, 10 = totally agree).

  21. Change in cardiorespiratory fitness

    Time frame: Baseline and 24 weeks

    Measured with an incremental VO2 protocol on exercise bike by COSMED Quark CPET plus OMNIA (COSMED®, Rome, Italy) (measured in mL/kg/min and Metabolic Equivalents [METs])

  22. Change in isometric strength

    Time frame: Baseline, 12 and 24 weeks

    Handgrip strength measured in kilograms using the Takei III Smedley Type Digital Dynamometer

  23. Change in lower limb muscle dynamic strength

    Time frame: Baseline and 24 weeks

    Lower limb muscle strength (legs and hips) measured in kg using eGym® machines (GmbH in Munich, Germany)

  24. Change in upper limb muscle dynamic strength

    Time frame: Baseline and 24 weeks

    Upper limb muscle strength (chest and arms) measured in kg using eGym® machines (GmbH in Munich, Germany)

  25. Change in lower limb muscle power strength

    Time frame: Baseline and 24 weeks

    Lower limb muscle power (legs and hips) measured in watts using eGym® machines (GmbH in Munich, Germany)

  26. Change in upper limb muscle power strength

    Time frame: Baseline and 24 weeks

    Upper limb muscle power (chest and arms) measured in watts using eGym® machines (GmbH in Munich, Germany)

  27. Change in self-reported physical fitness

    Time frame: Baseline and 24 weeks

    The International Fitness Scale (IFIS) will be used to assess self-reported physical fitness. This scale includes five elements that will employ a 5-point Likert scale to inquire about children's overall perception of their physical fitness, as well as their perception of their cardiorespiratory fitness, muscular fitness, speed-agility, and flexibility compared to their peers. The Likert scale will provide choices ranging from 'very poor' to 'poor,' 'average,' 'good,' and 'very good' physical fitness.

  28. Adherence to the Mediterranean Diet

    Time frame: Baseline and 24 weeks

    For assessing adherence to the Mediterranean Diet, the KIDMED index will be employed. This index provides a score on a scale of 0 to 12, with higher scores indicating stronger adherence.

  29. Change in dietary behavior

    Time frame: Baseline and 24 weeks

    Self-reported food intake will be assessed using a food-frequency questionnaire (FFQ). The daily consumption of food and beverages will be categorized into 12 groups: dairy, meat, fish, eggs, vegetables, fruit, starch, legumes, nuts, sweets, soft drinks, and alcoholic drinks.

  30. Change in body mass index

    Time frame: Baseline, 12 and 24 weeks

    Weight and height will be combined to report body mass index in kg/m^2

  31. Change in fat mass (percentage)

    Time frame: Baseline, 12 and 24 weeks

    Fat mass will be measured using a dual-energy X-ray absorptiometer (DXA) and expressed as a percentage.

  32. Change in fat mass (in kilograms)

    Time frame: Baseline, 12 and 24 weeks

    Fat mass will be measured using a dual-energy X-ray absorptiometer (DXA) and expressed in kilograms.

  33. Change in lean mass

    Time frame: Baseline, 12 and 24 weeks

    Fat mass in kilograms will be measured using a dual-energy X-ray absorptiometer (DXA)

  34. Change in subcutaneos adiposity

    Time frame: Baseline, 12 and 24 weeks

    Subcutaneos adiposity in cm^3 will be measured using a dual-energy X-ray absorptiometer (DXA)

  35. Change in visceral adiposity

    Time frame: Baseline, 12 and 24 weeks

    Visceral adiposity in cm^3 will be measured using a dual-energy X-ray absorptiometer (DXA)

  36. Change in bone mineral content

    Time frame: Baseline, 12 and 24 weeks

    Bone mineral content in grams will be measured using a dual-energy X-ray absorptiometer (DXA)

  37. Change in bone mineral density

    Time frame: Baseline, 12 and 24 weeks

    Bone mineral density will be measured in grams/cm^2 using a dual-energy X-ray absorptiometer (DXA)

  38. Change in blood lipids levels

    Time frame: Baseline and 24 weeks

    The following parameters will be evaluated: fasting total cholesterol, LDL-Cholesterol, HDL-Cholesterol, triglycerides, lipoprotein (a), and apolipoproteins A-I and B levels, measured in mg/dL.

  39. Change in fasting glucose

    Time frame: Baseline and 24 weeks

    Fasting glucose will be measured in mg/dL.

  40. Changes in liver enzymes

    Time frame: Baseline and 24 weeks

    The following parameters will be evaluated: alanine transaminase and aspartate aminotransferase.

  41. Change in inadvertent hypoglycemia

    Time frame: Baseline and 24 weeks

    The perception of hypoglycemia will be assessed using the Clarke test, which comprises eight questions with various potential answers. A score greater than 3 indicates impaired awareness of hypoglycemia.

  42. App usability

    Time frame: 24 weeks

    The usability of the app will be evaluated using the Spanish Version of the User Version of the Mobile Application Rating Scale (uMARS). This scale provides a comprehensive and objective measure of app usability and consists of 20 items. Each item is rated on a 5-point scale, ranging from 1 (inadequate) to 5 (excellent).

Sponsors and collaborators

Lead sponsor

Fundacion Miguel Servet

Other

Collaborators

  • Complejo Hospitalario de Navarra
  • Universidad Pública de Navarra

Registry information

Official study title

Effectiveness of the Mobile Application-delivered Resistance Program for Children and Adolescents With Type 1 Diabetes (Diactive-1) on Insulin Requirements: Protocol for a Randomized Controlled Trial

Acronym: Diactive-1

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Sep 21, 2023
Registry last updated
Dec 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.